Lactose (India) Ltd Share Price – BSE

Pharmaceuticals, Small Cap

Net profit of Lactose (India) rose 193.75% to Rs 1.88 crore in the quarter ended March 2026 as against Rs 0.64 crore during the previous quarter ended March 2025. Sales rose 64.82% to Rs 45.77 crore in the quarter ended March 2026 as against Rs 27.77 crore during the previous quarter ended March 2025.

For the full year,net profit rose 17.44% to Rs 6.06 crore in the year ended March 2026 as against Rs 5.16 crore during the previous year ended March 2025. Sales rose 40.28% to Rs 163.29 crore in the year ended March 2026 as against Rs 116.40 crore during the previous year ended March 2025.

Powered by Capital Market - Live News

Revenue from operations soared 64.81% year-on-year to Rs 45.77 crore in the quarter ended 31 March 2026.

Total expenses increased 58.28% year-on-year to Rs 43.67 crore during the quarter, compared with Rs 27.59 crore in the year-ago period. The cost of materials consumed stood at Rs 28.28 crore, up 59.23% YoY, while employee benefits expenses rose 5.37% to Rs 3.53 crore.

Profit before tax (PBT) stood at Rs 2.31 crore in Q4 FY26, registering a growth of 320% from Rs 0.55 crore reported in Q4 FY25.

For the full financial year FY26, the company posted a 17.44% rise in consolidated net profit to Rs 6.06 crore, while revenue rose 40.28% to Rs 163.29 crore compared with FY25.

Lactose (India) is a pharmaceutical company engaged in the business of manufacturing, trading and carrying out job work and manufacturing of pharmaceutical products.

Powered by Capital Market - Live News

Lactose (India) will hold a meeting of the Board of Directors of the Company on 20 May 2026.

Lactose (India) announced that an Extra Ordinary General Meeting (EGM) of the Company will be held on 28 March 2026.

Powered by Capital Market - Live News